Sodium butyrate inhibits pathogenic yeast growth and enhances the functions of macrophages

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 11, 2011, Pages 2573-2580

  Nguyen, Long Nam ^a   Lopes, Livia Cristina Liporagi ^a,b   Cordero, Radames J B ^a   Nosanchuk, Joshua D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Candida species; Cryptococcus neoformans; Fungal virulence; Yeast infection

Indexed keywords

AMPHOTERICIN B; BUTYRIC ACID; CASPOFUNGIN; FLUCONAZOLE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

ANIMAL CELL; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG POTENTIATION; FUNGAL VIRULENCE; FUNGUS GROWTH; GROWTH INHIBITION; HUMAN; INTRACELLULAR KILLING; MACROPHAGE FUNCTION; MELANOGENESIS; NONHUMAN; PHAGOCYTOSIS;

ANTIFUNGAL AGENTS; AZOLES; BIOFILMS; BUTYRATES; CANDIDA ALBICANS; CLOSTRIDIUM; CRYPTOCOCCUS NEOFORMANS; HISTONE DEACETYLASE INHIBITORS; LACTOBACILLUS; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; NITRIC OXIDE; PHAGOCYTOSIS; PHENOTYPE; REACTIVE OXYGEN SPECIES;

EID: 80054707876     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr358     Document Type: Article

References (38)

1. Gullo A. Invasive fungal infections: the challenge continues. Drugs 2009; 69 Suppl 1: 65-73.
2. Park BJ, Wannemuehler KA, Marston BJ et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23: 525-30.
3. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84.
4. Drummond DC, Noble CO, Kirpotin DB et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45: 495-528.
5. Zacchi LF, Schulz WL, Davis DA. HOS2 and HDA1 encode histone deacetylases with opposing roles in Candida albicans morphogenesis. PLoS One 2010; 5: e12171.
6. Wurtele H, Tsao S, Lepine G et al. Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy. Nat Med 2010; 16: 774-80.
7. Hnisz D, Majer O, Frohner IE et al. The Set3/Hos2 histone deacetylase complex attenuates cAMP/PKA signaling to regulate morphogenesis and virulence of Candida albicans. PLoS Pathog 2010; 6: e1000889.
8. Simonetti G, Passariello C, Rotili D et al. Histone deacetylase inhibitors may reduce pathogenicity and virulence in Candida albicans. FEMS Yeast Res 2007; 7: 1371-80.
9. Pfaller MA, Messer SA, Georgopapadakou N et al. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol 2009; 47: 3797-804.
10. Smith WL, Edlind TD. Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation. Antimicrob Agents Chemother 2002; 46: 3532-9.
11. Gacser A, Trofa D, Schafer W et al. Targeted gene deletion in Candida parapsilosis demonstrates the role of secreted lipase in virulence. J Clin Invest 2007; 117: 3049-58.
12. Nguyen LN, Trofa D, Nosanchuk JD. Fatty acid synthase impacts the pathobiology of Candida parapsilosis in vitro and during mammalian infection. PLoS One 2009; 4: e8421.
13. Martinez LR, Casadevall A. Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 2006; [50:] 1021-33.
14. Casadevall A, Cleare W, Feldmesser M et al. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother 1998; 42: 1437-46.
15. Derengowski LS, De-Souza-Silva C, Braz SV et al. Antimicrobial effect of farnesol, a Candida albicans quorum sensing molecule, on Paracoccidioides brasiliensis growth and morphogenesis. Ann Clin Microbiol Antimicrob 2009; 8: 13.
16. Cox RA, Best GK. Cell wall composition of two strains of Blastomyces dermatitidis exhibiting differences in virulence for mice. Infect Immun 1972; 5: 449-53.
17. Madesh M, Balasubramanian KA. Microtiter plate assay for superoxide dismutase using MTT reduction by superoxide. Indian J Biochem Biophys 1998; 35: 184-8.
18. Chandra J, Kuhn DM, Mukherjee PK et al. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001; 183: 5385-94.
19. Blankenship JR, Mitchell AP. How to build a biofilm: a fungal perspective. Curr Opin Microbiol 2006; 9: 588-94.
20. Mitchell AP. Dimorphism and virulence in Candida albicans. Curr Opin Microbiol 1998; 1: 687-92.
21. Chang YC, Penoyer LA, Kwon-Chung KJ. The second capsule gene of Cryptococcus neoformans, CAP64, is essential for virulence. Infect Immun 1996; 64: 1977-83.
22. Nosanchuk JD, Casadevall A. Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother 2006; 50: 3519-28.
23. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 2003; 133: 2485S-93S.
24. Sekhavat A, Sun JM, Davie JR. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. Biochem Cell Biol 2007; 85: 751-8.
25. Al-Dhaheri RS, Douglas LJ. Apoptosis in Candida biofilms exposed to amphotericin B. J Med Microbiol 2010; 59: 149-57.
26. McFadden DC, Casadevall A. Capsule and melanin synthesis in Cryptococcus neoformans. Med Mycol 2001; 39 Suppl 1: 19-30.
27. Zaragoza O, Chrisman CJ, Castelli MV et al. Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol 2008; 10: 2043-57.
28. Zaragoza O, Rodrigues ML, De Jesus M et al. The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol 2009; 68: 133-216.
29. Ochoa-Zarzosa A, Villarreal-Fernandez E, Cano-Camacho H et al. Sodium butyrate inhibits Staphylococcus aureus internalization in bovine mammary epithelial cells and induces the expression of antimicrobial peptide genes. Microb Pathog 2009; 47: 1-7.
30. Stempelj M, Kedinger M, Augenlicht L et al. Essential role of the JAK/STAT1 signaling pathway in the expression of inducible nitric-oxide synthase in intestinal epithelial cells and its regulation by butyrate. J Biol Chem 2007; 282: 9797-804.
31. Chen JS, Faller DV, Spanjaard RA. Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? Curr Cancer Drug Targets 2003; 3: 219-36.
32. Cabre E, Gassull MA. Nutrition in inflammatory bowel disease: impact on disease and therapy. Curr Opin Gastroenterol 2001; 17: 342-9.
33. Scheppach W, Bartram HP, Richter F. Role of short-chain fatty acids in the prevention of colorectal cancer. Eur J Cancer 1995; 31A: 1077-80.
34. Raqib R, Sarker P, Bergman P et al. Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci USA 2006; 103: 9178-83.
35. Fernandez-Rubio C, Ordoñez C, Abad-Gonzalez J et al. Butyric acid-based feed additives help protect broiler chickens from Salmonella Enteritidis infection. Poult Sci 2009; 88: 943-8.
36. Cummings JH, Macfarlane GT. The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol 1991; 70: 443-59.
37. Wong JM, de Souza R, Kendall CW et al. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006; 40: 235-43.
38. Miller AA, Kurschel E, Osieka R et al. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 1987; 23: 1283-7.